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Background: 17β-hydroxysteroid dehydrogenase type 10 (HSD10) has been shown to play a protective role in cells
undergoing stress. Upregulation of HSD10 under nutrient-limiting conditions leads to recovery of a homeostatic
state. Across disease states, increased HSD10 levels can have a profound and varied impact, such as beneficial in
Parkinson’s disease and harmful in Alzheimer’s disease. Recently, HSD10 overexpression has been observed in some
prostate and bone cancers, consistently correlating with poor patient prognosis. As the role of HSD10 in cancer
remains underexplored, we propose that cancer cells utilize this enzyme to promote cancer cell survival under
cell death conditions.
Methods: The proliferative effect of HSD10 was examined in transfected pheochromocytoma cells by growth
curve analysis and a xenograft model. Fluctuations in mitochondrial bioenergetics were evaluated by electron
transport chain complex enzyme activity assays and energy production. Additionally, the effect of HSD10 on
pheochromocytoma resistance to cell death was investigated using TUNEL staining, MTT, and complex IV
enzyme activity assays.
Results: In this study, we examined the tumor-promoting effect of HSD10 in pheochromocytoma cells.
Overexpression of HSD10 increased pheochromocytoma cell growth in both in vitro cell culture and an in vivo xenograft
mouse model. The increases in respiratory enzymes and energy generation observed in HSD10-overexpressing cells likely
supported the accelerated growth rate observed. Furthermore, cells overexpressing HSD10 were more resistant to
oxidative stress-induced perturbation.
Conclusions: Our findings demonstrate that overexpression of HSD10 accelerates pheochromocytoma cell
growth, enhances cell respiration, and increases cellular resistance to cell death induction. This suggests that
blockade of HSD10 may halt and/or prevent cancer growth, thus providing a promising novel target for cancer
patients as a screening or therapeutic option.
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While early detection and improved treatments have helped
manage certain types of cancer incidence and death rates
[1], this vast group of diseases still accounts for approxi-
mately 15% of all deaths worldwide each year [2]. Rapid
replication of abnormal cells and resistance to available an-
ticancer treatments are two prominent factors underlying
cancer aggressiveness [3]. As every patient’s cancer is
distinctively different, defining the underlying mechanisms
may implicate tumor-specific molecular agents. Identifica-
tion of such players could lead to novel targets for tailored
therapies unique to each individual.
The mechanisms underlying cancer have been widely
studied, with much emphasis placed on mitochondria [4].
Since Otto Warburg first showed that tumor cells exhibit in-
creased glycolytic adenosine triphosphate (ATP) production
and reduced oxidative phosphorylation [5], the mitochon-
drion has undergone thorough investigation to elucidate the
alterations promoting cancer. It is well known that constant
reactive oxygen species (ROS) exposure induces mutations
in mitochondrial DNA, which lead to cancer initiation and
metastasis [6]. While elevated ROS levels cause substantial
intracellular damage, tumor cells are capable of rebalancing
ROS production and elimination by activating antioxidants
[7]. By balancing ROS levels, tumor cells can undergo un-
hindered, continual proliferation. Moreover, cancer cells
display elevated inhibition of mitochondrial-mediated
cell death, regardless of ROS accumulation [8]. Modifica-
tion of the mitochondrial permeability transition pore
(MPTP) in malignant cells has been shown to render
cells more resistant to anticancer therapies [9], how-
ever, the mechanism underlying this resistance is not
fully understood.
HSD10 (17β-hydroxysteroid dehydrogenase type 10), also
known as ABAD (amyloid-β-binding alcohol dehydrogen-
ase) and MHBD (2-methyl-3-hydroxybutyryl-CoA dehydro-
genase), is a mitochondrial enzyme that catalyzes the
oxidation of a wide variety of alcohols, fatty acids, and
steroids [10]. Our group originally identified HSD10 as a
single chain, ≈27 kilodalton polypeptide capable of bind-
ing amyloid-β [11,12]. HSD10 is crucial for the mainten-
ance of cellular homeostasis, and overexpression has been
shown to provide a protective effect in cells undergoing
nutritional stress [13]. HSD10 belongs to the short-chain
dehydrogenase/reductase superfamily 17β-hydroxysteroid
dehydrogenase (HSD17B). These alcohol oxidoreductases
catalyze the dehydrogenation of 17-hydroxysteroids [14].
Several HSD17B family members have been implicated in
breast [15-17], endometrial [18], and colorectal cancers [19],
suggesting that this group of enzymes is important in
different types of cancer. HSD10 was shown to be elevated
in certain prostate carcinomas and osteosarcomas [20,21],
indicative of a potential role in cancer. Furthermore, HSD10
may promote tumorigenesis and aggressiveness, as elevatedHSD10 levels were observed in prostate-to-bone metastases
compared to non-malignant prostate and primary prostate
tumor tissue [22]. While HSD10 remains underexplored in
all cancer types, the current data in bone and prostate can-
cers strongly suggest that HSD10 may be utilized in cancer
cells for protection against cell death and enhancement of
unrestricted growth.
Based on these observations, we postulate that HSD10
overexpression enhances cancer cell growth and resistance
to cell death. To examine the tumorigenic capability of
HSD10, we selected the rat adrenal gland (pheochromocy-
toma) tumor cell line, PC-12. Here, we provide evidence
that HSD10 mediates pheochromocytoma cell growth in
cell culture and in a mouse model. Furthermore, we have
identified a novel HSD10 binding partner, Cyclophilin D
(CypD), a regulatory component of the MPTP, which may
provide increased resistance to cell death in tumor cells.
Now that we have demonstrated the effect of overexpress-
ing HSD10 in non-malignant tumor cells, our future efforts




Reagents were obtained from the following sources: RPMI-
1640 medium, Hank’s balanced salt solution (HBSS), 0.25%
Trypsin-EDTA, heat-inactivated horse serum, fetal bovine
serum (FBS), G418 supplement, Lipofectamine 2000, Mito
Tracker Red, Mito Tracker Green, tetramethylrhodamine
methyl ester (TMRM) from Invitrogen Co. (Grand Island,
NY); Bicinchoninic Acid (BCA) protein assay from
Pierce Chemical Company (Rockford, IL); CellTiter 96
Non-Radioactive Cell Proliferation Assay from Promega
Co. (Madison, WI); Lentiviral Packaging Mix, Tert-Butyl
hydroperoxide (TBH), Coenzyme Q1, Coenzyme Q2 from
Sigma-Aldrich Co. (St. Louis, MO); Hydrogen peroxide
(H2O2), Super Signal West Pico Chemiluminescent
Substrate from Thermo Fisher Scientific Co. (Waltham,
MA); ATP Bioluminescence Assay Kit HS II, In Situ Cell
Death Detection Kit, Fluorescein from Roche Applied
Science Co. (Indianapolis, IN); Signal transduction anti-
bodies from Cell Signaling Technology Co. (Danvers, MA).
All other chemicals used were of the highest purity com-
mercially available.
Generation of stably transfected PC-12 cells overexpressing
HSD10
The rat pheochromocytoma (adrenal gland tumor) cell line
PC-12 (ATCC® CRL-1721, Manassas, VA) was used for
stable transfection of HSD10 as formerly described
[13]. In brief, PC-12 cells (105 cells) were transfected
with pcDNA3/(human) wild-type HSD10, or pcDNA3
alone (vector) previously linearized with SmaI, using
Lipofectamine 2000 [23]. 48 hours after transfection,
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supplemented with 1 mg/ml G418. After 1–2 weeks, single
clones were isolated, and cells were separated with trypsin,
subjected to limiting dilution, and replated in medium con-
taining 1 mg/ml G418 for 2–4 weeks. After, cells were
maintained in RPMI-1640 medium supplemented with
10% horse serum, 5% FBS, and 1 mg/ml G418 in a humidi-
fied 37°C, 5% CO2 environment.
Generation of lentiviral transfected PC-12 cells
under-expressing HSD10
HEK 293 T cells (ATCC® CRL-11268; 2.5 × 105 cells/well
in a 6-well plate) were transfected with HSD10 shRNA
(HSD17B10 MISSION® shRNA Bacterial Glycerol Stock,
Human, SHCLNG NM_004493.2-751s21c1 TRCN000031
8938, Sequence: CCGGCATCGAGAACCCATTCCTCA
ACTCGAGTTGAGGAATGGGTTCTCGATGTTTTT
G; Sigma-Aldrich) or control shRNA (MISSION® TRC2
pLKO.5-puro Non-Mammalian shRNA Control Plasmid
DNA, SHC202; Sigma-Aldrich) using Lipofectamine 2000
and Lentiviral Packaging Mix. Cell media was harvested at
36 and 72 hours post-transfection. PC-12 cells (105 cells/
well in a 12-well plate) were infected with HSD10 shRNA
and non-mammalian shRNA media over 10 days with
continual passaging, and then were maintained in RPMI-
1640 medium supplemented with 10% horse serum and
5% FBS in a humidified 37°C, 5% CO2 incubator, with
shRNA viral media added to cell cultures once a week.
Characterization of transfected PC-12 cell lines
All PC-12 cell lines, between passages 1–8, were character-
ized using immunoblotting to determine HSD10 expression
level, immunofluorescence staining to verify HSD10 expres-
sion level and localization, and growth curves.
Immunoblotting
Whole cell lysates were prepared from harvested cells.
Cells were washed twice with pre-chilled phosphate buff-
ered saline (PBS), followed by detachment with a scraper
and sonication. Lysates were measured for protein con-
centration using the BCA protein assay. Proteins from the
lysates were separated on NuPAGE® Novex® Bis-Tris 10%
and 12% gels (Invitrogen) by SDS-PAGE. Gels were trans-
ferred to 0.45 μm nitrocellulose membranes (Thermo
Fisher Scientific) and probed with rabbit anti-HSD10 IgG
(generated in our laboratory [11], 1:3000) and mouse
anti-Actin (1:8000). HSD10 was visualized using a chemi-
luminescence mixture and FluorChem HD2 imaging sys-
tem (ProteinSimple, Santa Clara, CA).
Immunofluorescence staining
Cells (2 × 104 cells/well) were grown in 8-well chamber
slides until 70% confluent, and then incubated with 100
nM Mito Tracker Red for 30 minutes, followed by fixationin 4% paraformaldehyde and 0.1% Triton X-100 for
30 minutes. Fixed cells were incubated with rabbit anti-
HSD10 IgG (1:200, generated in our laboratory) at 4°C
overnight. The same concentration of non-immune IgG
was used as a control. Secondary antibody (Alexa Fluor
488 anti-rabbit IgG, 1:2000, Invitrogen) was applied to the
cells followed by confocal microscopy (Leica Microsystems,
Buffalo Grove, IL). The intensity of fluorescence (ex: 581 nm,
em: 644 nm for Mito Tracker Red; ex: 499 nm, em: 520 nm
for HSD10) was recorded to determine HSD10 expression
and mitochondrial localization.Growth curves
Cells were plated in 100-mm dishes at a density of 2.5 × 105
cells/dish. One dish was chosen each consecutive day
to be counted. The cells in the dish were detached with
Trypsin, centrifuged, and resuspended in 1 ml of DMEM
media, followed by counting using a hemocytometer.Mitochondrial function and cell death assays
Mitochondrial membrane potential and bioenergetics
were determined as previously described [24,25] in the
PC-12 altered cell lines at passages 1–8.Fluorescence staining of TMRM to examine mitochondrial
membrane potential
Cells (2 × 104 cells/well) were grown in 8-well chamber
slides until 70% confluent, and then incubated with 150
nM Mito Tracker Green (Invitrogen) and 100 nM TMRM
(non-quench mode) for 30 minutes, followed by washing
twice with HBSS media. Cells were imaged live by confocal
microscopy and the intensity of fluorescence (ex: 490 nm,
em: 516 nm for Mito Tracker Green; ex: 490 nm, em:
550 nm for TMRM) was recorded to determine the uncol-
lapsed proton gradient.Measurement of cellular ATP
Cellular ATP levels were measured using Bioluminescence
Assay Kit HS II following the manufacturer’s instructions
as we previously described [25]. Briefly, cells (30 × 104
cells/well) were grown in 6-well plates until fully conflu-
ent. Cells were washed twice with ice-cold PBS, followed
by the addition of 50 μl/well of ATP Lysis Buffer. Cells
were harvested, incubated on ice for 20 minutes, and then
centrifuged. Protein content of the supernatant was deter-
mined using the BCA protein assay. Proportional amounts
of sample were added to a 96-well ATP plate (25 μl/well).
The reaction solution was brought to 50 μl/well with the
addition of ATP Dilution Buffer. ATP levels were deter-
mined using an LMax II 384 Microplate Reader and
SoftMax Pro (Molecular Devices, Sunnyvale, CA).
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The CellTiter 96 Non-Radioactive Cell Proliferation
Assay kit was used to measure metabolic activity. Cells
(104 cells/well) were plated in 96-well plates 48 hours
prior to the experiment. For cellular resistance experi-
ments, H2O2 (0.1, 0.25, 0.5, 0.75, and 1 mM) and TBH
(0.1 and 0.25 mM) were added to cells 24 hours prior to
incubation with 15 μl/well of MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye solu-
tion for 4 hours. Successively, 100 μl/well of solubilization
solution was added to stop the reaction, and then the
plates were incubated for 1 hour. The change in absorb-
ance at 570 nm was recorded using a 96-well Synergy HT
Multi-Mode Microplate Reader (BioTek Instruments,
Winooski, VT). A reference wavelength of 650 nm was
taken to reduce background.
Measurement of enzyme activities associated with respiratory
chain complexes
Briefly, cells (106 cells/dish) were grown in 150-mm dishes
until fully confluent. For measurement of complex I-IV en-
zymatic activities in response to oxidative stress, 0.75 mM
of H2O2 was added to cells and incubated for 1, 6, 16, and
24 hours before collection. Cells were washed twice with
pre-chilled PBS, and then harvested, centrifuged, and sus-
pended in 100 μl of isolation buffer containing 225 mM
D-mannitol, 75 mM sucrose, and 2 mM K2HPO4. A work-
ing solution of 25 mM potassium (K) buffer (3 M KCl, 1 M
Tris–HCl, pH 7.4, and 0.5 M EDTA) was used for complex
I, II, III, and IV assays as described [25]. An Ultrospect
3100 Pro-spectrophotometer (Amersham Biosciences,
Piscataway, NJ) was used to measure the change in absorb-
ance for all complexes. Background levels were measured
in the absence of cell suspensions. All complex enzyme
activities are expressed as nanomoles of substrate oxidized
per mg−1 protein min−1 ml−1 (nmol/mg protein/min/ml).
Complex I (NADH-ubiquinone oxidoreductase)
Cell lysate (30–50 μg of protein/ml) was added to a
cuvette containing 0.5 ml of reaction buffer (5 mM
MgCl2, 2 mM KCN, 0.13 mM NADH, and 2 μg/ml
Antimycin; diluted in K buffer). The reaction was
started by the addition of Coenzyme Q1 (2 μl of 65 μM
solution). At 180 seconds, 2 μl of Rotenone (2 μg/ml) was
added to the cuvette. The change in absorbance at
340 nm, resulting from the oxidation of NADH, was
measured using a kinetic program with 20 second inter-
vals and a total of 18 readings.
Complex II (succinate-ubiquinone oxidoreductase)
Cell suspensions (30–50 μg of protein/ml) were added
to a 1.5 ml microcentrifuge tube containing 0.5 ml of
reaction solution 1 (5 mM MgCl2 and 20 mM succinate;
diluted in K buffer), and then incubated in a 37°C waterbath for 10 minutes. After transferring the cell solution to
a cuvette, the reaction was started by the addition of 8 μl
of reaction solution 2 (2 μg/ml Antimycin, 2 μg/ml Rote-
none, 2 mM KCN, and 50 μM Dichlorophenlindophenol).
At 180 seconds, 2 μl of Coenzyme Q2 (65 μM) was added
to the cuvette. The change in absorbance at 600 nm,
resulting from the reduction of Dichlorophenlindophenol,
was measured using a kinetic program with 20 second
intervals and a total of 18 readings.
Complex III (ubiquinol-cytochrome c oxidoreductase)
The reaction was started by the addition of 2 μl of
Coenzyme Q2 (65 μM) to a cuvette containing 0.5 ml
of reaction buffer (5 mM MgCl2, 2 mM KCN, 15 μM
cytochrome c, 2 μg/ml of Rotenone, and 0.6 mM
Dodecyl-β-d-maltoside; diluted in K buffer). At 60 sec-
onds, a cell suspension (30–500 μg of protein/ml) was
added to the cuvette. The change in absorbance at 550 nm,
resulting from the reduction of cytochrome c, was mea-
sured using a kinetic program with 20 second intervals and
a total of 12 readings.
Complex IV (cytochrome c oxidase)
Cell lysate (30 μg of protein/ml) was added to a cuvette
containing 0.475 ml of assay buffer (10 mM Tris–HCl,
pH 7.0, and 120 mM KCl), and the reaction volume was
brought to 0.525 ml with enzyme dilution buffer (10 mM
Tris–HCl, pH 7.0, and 250 mM sucrose). The reaction
was started by the addition of 25 μl of ferrocytochrome c
substrate solution (0.22 mM). The change in absorbance
at 550 nm, resulting from the oxidation of cytochrome c,
was measured using a kinetic program with a 5 second
delay, 10 second intervals, and a total of 6 readings.
Citrate synthase
Cells in 100-mm dishes were washed twice with ice-cold
PBS, and cells were harvested, centrifuged, and suspended
in 100 μl of isolation buffer containing 1 M Tris, pH 7.4,
and 3 M KCl. The reaction was started by the addition of
cell lysate (10–30 μg of protein/ml) to a cuvette contain-
ing 150 μl of assay buffer (100 mM Tris, pH 7.4, 0.17 mM
Oxaloacetic acid, 0.2 mM Acetyl CoA). The change in
absorbance at 232 nm was measured using a kinetic pro-
gram with 60 second intervals and a total of 8 readings.
TUNEL staining
The In Situ Cell Death Detection Kit, Fluorescein
(Roche) was used as described. Cells (2 × 104 cells/well)
were grown in 8-well chamber slides until 70% confluent.
Following incubation for 24 hours with 0.75 mM H2O2,
the cells were fixed in 4% paraformaldehyde for 1 hour.
Fixed cells were permeabilisated for 2 minutes on ice,
followed by incubation with 75 μl TUNEL reaction mix-
ture for 1 hour at 37°C. After washing twice with PBS
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cells were imaged via confocal microscopy and the inten-
sity of fluorescence (ex: 488 nm, em: 565 nm for TUNEL;
ex: 358 nm, em: 461 nm for DAPI) was recorded to deter-
mine cells undergoing apoptotic cell death.
Cyclophilin D studies
Immunoblotting, co-immunofluorescence, and co-immu-
noprecipitation assays were performed in the PC-12
altered cell lines at passages 1–8 to investigate the role
of CypD.
Co-immunofluorescence staining
Cells (2 × 104 cells/well) were grown in 8-well chamber
slides until 70% confluent, and then fixed in 4% parafor-
maldehyde and 0.1% Triton X-100 for 30 minutes. Fixed
cells were incubated with mouse anti-HSD10 (1:100, gener-
ated in our laboratory) and rabbit anti-CypD (1:200, gene-
rated in our laboratory), mouse anti-HSD10 (1:100)
and rabbit anti-SODII (1:1000), or mouse anti-Hsp60
(1:1000) and rabbit anti-CypD (1:200) overnight, and
then incubated with secondary antibodies (Alexa Fluor
488 anti-rabbit and Alexa Fluor 594 anti-mouse (1:2000,
Invitrogen). DAPI was applied to the cells for 5 minutes
followed by confocal microscopy. The intensity of fluores-
cence (ex: 499 nm, em: 520 nm for HSD10; ex: 343 nm,
em: 442 nm for CypD; ex: 494 nm, em: 518 nm for SODII;
ex: 495 nm, em: 519 nm for Hsp60; ex: 358 nm, em:
461 nm for DAPI) was recorded to determine HSD10 and
CypD expression and localization to the mitochondrial
markers, SODII and Hsp60.
Co-immunoprecipitation
Briefly, cells (106 cells/dish) were grown in 150-mm dishes
until fully confluent. Cells were washed twice with pre-
chilled PBS, and then harvested, centrifuged, and sus-
pended in 250 μl Co-Immunoprecipitation (Co-IP) buffer
containing 150 mM NaCl, 50 mM Tris–HCl, pH 7.4,
1 mM EDTA, 0.5% NP-40, and 100X protease inhibitor
(EMD Millipore). Cells were frozen and thawed in 250 μl
Co-IP buffer for 10 cycles, followed by brief sonication and
30 minutes of lysis on ice. After centrifugation at 8000 × g
for 5 minutes at 4°C, lysates were measured for protein
concentration using the BCA protein assay and subjected
to co-immunoprecipitation with antibodies. Samples with
500 μg protein extracts within 500 μl Co-IP buffer were in-
cubated overnight with pull-down antibodies (rabbit anti-
HSD10, generated in our laboratory; mouse anti-CypD,
Abcam; rabbit IgG or mouse serum), while rotating at 4°C.
The immunocomplexes were pulled out using Protein
A/G-sepharose beads for 2 hr. Next, the immuno-
precipitates were washed three times with Co-IP buffer,
collected by brief centrifugation, and dissolved in denaturing
sample buffer. Immunoblotting was used to reveal theimmunoprecipitated proteins as previously described, and
the antibodies used were mouse anti-CypD (1:8000), rabbit
anti-HSD10 (1:3000), and mouse anti-Actin (1:8000).
Animal studies
All animals were housed under pathogen-free conditions
according to AAALAC guidelines. All animal-related ex-
periments were performed in full compliance with institu-
tional guidelines and approved by the Animal Care and
Use Committee of the University of Kansas. Two-month
old female severe combined immunodeficient (SCID)
mice were purchased from Jackson Laboratory (Bar
Harbor, ME).
Control and HSD10-overexpressing PC-12 cells were
grown in 150-mm dishes until fully confluent. Cells were
collected and inoculated into SCID mice via mammary
fat pad injection after shaving of the area and alcohol
preparation of the skin, using a sterile 22-gauge needle
with 0.1 ml cell suspension of 1 × 106 cells with manual
restraint [26]. Mice were weighed and tumor size was
measured using a caliper twice per week for a total of
32 days. Tumor volume was calculated using the for-
mula: (length x width2)/2 [27]. Mice were imaged with
an In-Vivo Multispectral FX PRO imaging system
(Carestream, Woodbridge, CT) on day 30 of the experi-
ment, 24 hours post-injection of 15 nmol of IRDye
800CW 2-deoxyglucose (2-DG, Li-Cor Biosciences,
Lincoln, NB) optical probe [28] given via tail vein injec-
tion. An excitation filter of 760 nm and emission filter
of 830 nm was applied for Near Infrared imaging to
visualize tumor growth.
Statistics
Paired t tests were used for statistical comparison of
empty vector with HSD10 overexpression groups, and
control shRNA with HSD10 shRNA groups. Unpaired t
tests were used to analyze all animal data. All data was
analyzed using StatView 5.0.1 Windows software (SAS
Institute, Cary NC) and results are reported as mean ± SE.
P < 0.05 was considered significant.
Results
Characterization of PC-12 HSD10-transfected cell lines
After generating PC-12 cancer cell lines expressing
either an empty vector (EV) or an HSD10 overexpression
(HSD10 ov) vector, we first examined HSD10 protein ex-
pression levels in the cells using immunoblot analysis.
HSD10 protein expression was increased by 3-fold in
HSD10 ov cells compared to EV cells (Figure 1A). The
level of HSD10 expression was further verified by im-
munofluorescence staining (Figure 1B). The intensity of
HSD10 staining was significantly enhanced in HSD10
ov cells in comparison with EV cells (Figure 1C). In
addition to confirming increased levels of HSD10 in the
Figure 1 Characterization of HSD10-transfected cell lines. A. Empty vector (EV) and HSD10 overexpression (HSD10 ov) whole cell lysates were
analyzed for HSD10 protein expression via immunoblotting. β-actin was used as the loading control, and HSD10 expression was normalized to actin
(n = 4). B. Confocal microscopy demonstrating immunofluorescence staining of HSD10 alone (green), Mito Tracker Red alone (red), and these two
antigens co-localized (yellow) in EV and HSD10 ov cells. Scale bar in B: 30 μm. C. Quantification of HSD10 immunofluorescence staining (depicted in B)
displayed as fold increase (n = 5). D. Control shRNA and HSD10 shRNA whole cell lysates were analyzed for HSD10 protein expression via immunoblotting.
β-actin was used as the loading control, and HSD10 expression was normalized to actin (n = 4). E. Confocal microscopy demonstrating
immunofluorescence staining of HSD10 alone (green), Mito Tracker Red alone (red), and these two antigens co-localized (yellow) in control shRNA and
HSD10 shRNA cells. Scale bar in E: 30 μm. F. Quantification of HSD10 immunofluorescence staining (depicted in E) displayed as fold increase (n = 5).
Data presented as mean ± SE. *P < 0.01, **P < 0.001, ***P < 0.0001 verses control group.
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cence assay confirmed the localization of HSD10 to
mitochondria as is depicted in the merged picture of
Figure 1B.
To thoroughly examine the effect of HSD10 in cancer,
we used lentiviral transfection to knockdown HSD10 in
PC-12 cells. We again characterized the cells via immuno-
blot analysis, showing that HSD10 protein expression was
significantly reduced by 80% in HSD10 shRNA-transfected
cells in comparison with unrelated control shRNA-
transfected cells (Figure 1D). The level of HSD10
knockdown was also confirmed by immunofluorescencestaining of HSD10 (Figure 1E), which showed that
the intensity of HSD10 staining was decreased in
HSD10 shRNA cells compared to control shRNA cells
(Figure 1F).
As HSD10 is typically located in mitochondria
[12,29], specific localization likely promotes this en-
zyme’s multifunctional abilities within the cell. Therefore,
our observation that HSD10 localizes to mitochondria in
PC-12 HSD10-transfected cells suggests that fluctuating
HSD10 levels may influence mitochondrial function.
Thus, we next sought to examine the effect altered
HSD10 expression has on mitochondrial bioenergetics.
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bioenergetics and membrane potential in PC-12 cells
To examine the effect of HSD10 on mitochondrial func-
tion, we assessed the enzyme activities of complexes I, II,
III, and IV of the electron transport chain (ETC.). Com-
plexes I, III, and IV are proton pumps, which generate the
transmembrane proton gradient necessary to drive ATP
generation by ATP synthase. Any changes in the ETC. sys-
tem would impact mitochondrial ATP generation and any
ensuing mitochondrial processes. While the enzyme ac-
tivities of complexes I, II, and III remained unchanged
(Figure 2A-C), complex IV activity was significantly in-
creased in HSD10 ov cells compared with EV cells
(Figure 2D), suggesting an enhancement in the ETC.
system of HSD10-overexpressing cells. Conversely,
HSD10 shRNA cells displayed significantly decreased
ETC. complex enzyme activity in all of the complexesFigure 2 Assessment of mitochondrial bioenergetics in HSD10-transfe
and IV (D) enzyme activities were assessed in EV, HSD10 ov, control shRNA
each assay), showed that complex IV activity is enhanced in HSD10 ov cells
E. Densitometry of citrate synthase enzyme activity (n = 5) showed no chan
HSD10 shRNA cells. F. Densitometry of ATP activity (n = 6) demonstrate
HSD10 shRNA cells. G. Densitometry of MTT reduction (n = 4) exhibited
presented as mean ± SE. *P < 0.01, **P < 0.001, ***P < 0.0001 versus EV ameasured, in comparison to control shRNA cells
(Figure 2A-D). This reduction in all of the complexes
indicates that HSD10 is important for cancer cell
functionality, and would likely have a substantial im-
pact on subsequent mitochondrial processes.
Citrate synthase enzyme activity, which often serves as
a quantitative enzyme marker for the presence of intact
mitochondria, was similar between HSD10 ov cells and
EV cells (Figure 2E). This indicated that, despite an
overabundance of HSD10, the PC-12 cells were healthy.
Next, we examined how the increase in complex IV ac-
tivity impacted ATP production. In conjunction with the
complex IV data observed in Figure 2D, the level of ATP
was significantly elevated in HSD10 ov cells compared to
EV cells (Figure 2F), demonstrating a possible increase in
energy generation in HSD10-overexpressing PC-12 cells.
On the other hand, citrate synthase enzyme activity, whichcted cell lines. Electron transport chain complex I (A), II (B), III (C),
, and HSD10 shRNA cells. Results, displayed as fold increase (n = 5 for
and all ETC. complex activities are decreased in HSD10 shRNA cells.
ge in activity between EV and HSD10 ov cells, and reduced activity in
d that ATP levels are increased in HSD10 ov cells and diminished in
similar reduction of MTT by all HSD10-transfected cell lines. Data
nd control shRNA groups.
Carlson et al. BMC Cancer  (2015) 15:166 Page 8 of 15serves as a measurement of mitochondrial fitness, was re-
duced in HSD10 shRNA cells (Figure 2E). This indicates
that HSD10 knockdown disrupts mitochondrial function.
Similarly, ATP production was diminished in HSD10
shRNA cells compared to control shRNA cells (Figure 2F),
which was expected in view of the decreased activity
observed in all of the ETC. complexes in Figure 2A-D.
As ATP is a key driver for many mitochondrial and
cellular processes, we next examined the effect of
HSD10 on cell viability by measuring cellular metabolic
activity using the MTT reduction assay. MTT reduction
levels remained similar between HSD10 ov cells and EV
cells after 24 hours, indicating comparable cell viability
(Figure 2G). Furthermore, the change in MTT reduction
between control shRNA and HSD10 shRNA cells was
not statistically significant after 24 hours (Figure 2G).
We further assessed mitochondrial function by exam-
ining the effect of HSD10 on mitochondrial membrane
potential using the cell-permeant dye, TMRM. This redFigure 3 Examination of mitochondrial membrane potential in HSD10
immunofluorescence staining of mitochondrial membrane potential with TMR
co-localized (yellow) in EV and HSD10 ov cells. Scale bar in A: 30 μm. B. Quant
as the percentage of intensity of fluorescence (n = 4). C. Confocal microscopy d
potential with TMRM alone (red), Mito Tracker Green alone (green), and these t
Scale bar in C: 30 μm. D. Quantification of TMRM immunofluorescence staining
(n = 4). Data presented as mean ± SE. *P < 0.05 versus control group.dye is readily taken up by active mitochondria and emits a
stronger fluorescence in mitochondria with intact mem-
branes [30], and co-localizes with Mito Tracker Green
(Figure 3A). HSD10 ov cells displayed enhanced TMRM
staining as opposed to the normal levels observed in EV
cells (Figure 3A-B). Alternatively, HSD10 shRNA cells dis-
played a decrease in TMRM staining intensity compared
to control shRNA cells (Figure 3C-D). Due to the signifi-
cant increase in TMRM fluorescence observed in HSD10
ov cells, we propose that HSD10 overexpression promotes
mitochondrial membrane hyperpolarization. Whereas loss
of mitochondrial membrane potential can induce cell
death pathways, we suggest that hyperpolarization me-
diated in part by HSD10 would lead to protection
against induction of cell death. In HSD10 shRNA cells,
there is considerably less HSD10 present within mito-
chondria; hence we theorize that HSD10 knockdown
would induce mitochondrial membrane depolarization,
thus increasing the chance of cell death induction.-transfected cell lines. A. Confocal microscopy demonstrating
M alone (red), Mito Tracker Green alone (green), and these two antigens
ification of TMRM immunofluorescence staining (depicted in A) displayed
emonstrating immunofluorescence staining of mitochondrial membrane
wo antigens co-localized (yellow) in control shRNA and HSD10 shRNA cells.
(depicted in C) displayed as the percentage of intensity of fluorescence
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culture and in vivo
After evaluating the effect of HSD10 on mitochondrial
processes, we determined the effect of HSD10 overexpres-
sion on cancer cell growth. Using in vitro cell culture, we
performed growth rate curves using both PC-12 HSD10
overexpression and PC-12 HSD10 knockdown cell lines.
As shown in Figure 4A, HSD10 ov cells grew at a signifi-
cantly faster rate compared to EV cells over seven days.
Knockdown of HSD10 led to a considerable decrease in
growth rate compared with control shRNA cells (Figure 4B).
Taken together, these results suggest that HSD10 promotes
pheochromocytoma cell growth in cell culture and that
knockdown of HSD10 has a reverse effect on cancer cell
growth.
Xenograft tumor models were used to validate the role
of HSD10 on cancer cell growth in vivo. SCID miceFigure 4 Effect of HSD10-modification on in vitro cell growth and in v
HSD10 ov cells measured over seven days demonstrated that HSD10 ov ce
(n = 9). B. Growth curve displaying the number of control shRNA and HSD1
cells grew slower than control shRNA cells. Results depicted as cells × 104
mammary fat pad tissue of 20 two-month old female SCID mice. Day 30 tu
HSD10 ov (right mouse) cells demonstrated considerable tumor growth in
Visualization of tumors was performed 24 hours post-injection of 15 nmol
point to tumors. D. Quantification of tumor growth in all SCID mice injecte
32 days, depicted in tumor volume (mm3). Data presented as mean ± SE. *inoculated with HSD10 ov cells exhibited drastically lar-
ger tumors compared to mice with EV tumor xenografts
which displayed very minimal growth (Figure 4C-D).
These results demonstrate that HSD10 overexpression
accelerates tumor development in vivo, providing further
evidence that HSD10 is an important tumorigenic medi-
ator in the transformation of non-malignant adrenal
gland cancer.
HSD10 overexpression enhances PC-12 cell resistance to
oxidative stress stimuli
To assess resistance to cell death, we treated the PC-12
HSD10 overexpression cells with various concentrations
of H2O2 and tert-butyl hydroperoxide (TBH) for 24 hours
to stimulate oxidative stress conditions as cancer cells are
typically exposed to higher oxidative stress levels [31].
While cell viability steadily decreased for both cellivo tumor growth. A. Growth curve depicting the number of EV and
lls grew faster in cell culture. Results displayed as cells × 104 per ml
0 shRNA cells measured over seven days showed that HSD10 shRNA
per ml (n = 9). C. EV and HSD10 ov cells were injected into the
mor growth in two SCID mice inoculated with EV (left mouse) or
the HSD10 tumor mouse when observed beside the EV tumor mouse.
2-DG optical dye with an In-Vivo Multispectral FX PRO imager. Arrows
d with EV (n = 8) or HSD10 ov (n = 12) cells grown over a total of
P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus control group.
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demonstrated significantly higher reduction of MTT at
0.75 and 1 mM concentrations of H2O2 compared to EV
cells (Figure 5A). Treatment of the cells with TBH showed
similar results, with HSD10 ov cells reducing considerably
more MTT compared to EV cells at the lowest dosage of
TBH given (0.1 mM, Figure 5B). Thus, while these two
oxidative stressors reduce cell viability in both EV and
HSD10 ov cells, PC-12 cells with HSD10 overexpression
exhibited more resistance to chemical-induced oxidative
stress.
We tested this cellular resistance further by examining
complex IV enzyme activity. We chose to treat the cells
with 0.75 mM of H2O2 as the amount of MTT reduced
by EV cells remained at a higher level compared to theFigure 5 Effect of HSD10 overexpression on cellular resistance to dea
HSD10 ov cells treated with A) 0, 0.1, 0.25, 0.5, 0.75, and 1 mM H2O2 (n = 3 for
groups). Results demonstrated that HSD10 ov cells were more resistant to oxi
was assessed in EV and HSD10 ov cells treated with 0.75 mM H2O2 for C) 24 h
displayed as nmol/mg protein/min/ml, showed that complex IV activity is enh
microscopy demonstrating TUNEL staining of cells undergoing apoptosis (green
(merged) in EV and HSD10 ov cells, treated with 0 mM and 0.75 mM H2O2 for 2
in E) displayed as the percentage of TUNEL positive cells (n = 4). Data presented
(A-D) and versus EV and HSD10 ov non-treatment groups (F); #P < 0.01 versus Eamount seen at 1 mM H2O2 (Figure 5A) and the lowest
dose of TBH used (Figure 5B). As a starting point, we
assessed complex IV activity in the PC-12 HSD10-
overexpressing cells treated with 0.75 mM of H2O2 for
24 hours. However, H2O2 treatment showed no difference
in enzyme activity between the two groups (Figure 5C).
Rationalizing that any changes in enzymatic activity would
likely be more visible earlier in the chemical treatment, we
assessed the activity of complex IV at several time points
during the 24 hour period. As speculated, complex IV
enzyme activity was significantly increased in HSD10 ov
cells compared to EV cells after just one hour of H2O2
treatment (Figure 5D). Indeed, this difference in activity
occurred earlier into the treatment period as the differ-
ence between HSD10 ov and EV cells at 16 hours of H2O2th-inducing stimuli. A-B. Densitometry of MTT reduction in EV and
all groups), and B) 0, 0.1, and 0.25 mM TBH for 24 hours (n = 3 for all
dative stress-induced cell death. C-D. ETC. complex IV enzyme activity
ours (n = 3), and D) 0, 1, 6, and 16 hours (n = 6 for all time points). Results,
anced in HSD10 ov cells under an oxidative stress condition. E. Confocal
), nuclear staining with DAPI (blue), and these two antigens co-localized
4 hours. Scale bar in E: 30 μm. F. Quantification of TUNEL staining (depicted
as mean ± SE. *P < 0.05, **P < 0.01, ***P < 0.0001 versus EV control group
V treatment group (F).
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similar levels (Figure 5D). This data implies that HSD10
overexpression aids cell survival under oxidative stress set-
tings, conceivably by elevating and/or maintaining mito-
chondrial bioenergetics, such as ETC. activity and ATP
generation, during this death-inducing condition.
To provide further evidence for this concept, we per-
formed TUNEL staining in EV and HSD10 ov cells with-
out treatment, and EV and HSD10 ov cells treated with
0.75 mM H2O2 for 24 hours (Figure 5E). As expected,
both EV and HSD10 ov cells treated with H2O2 exhib-
ited higher percentages of cells undergoing apoptosis
(Figure 5F), compared with the untreated matched con-
trol groups. However, the HSD10 ov treatment group
had significantly less TUNEL staining compared to the
EV treatment group (Figure 5F, #p-value), indicating that
cells overexpressing HSD10 are more protected from
apoptosis induction. The data presented here support
the concept that HSD10 overexpression increases pheo-
chromocytoma cell resistance to cell death induced by
oxidative stress.
HSD10 overexpression increases HSD10-CypD complex
formation in PC-12 cells
Next, we sought to determine the mechanism behind the
ability of HSD10 to regulate cancer cell growth and cell
death resistance associated with mitochondrial function.
We examined the relationship between HSD10 and CypD,
which is a modulator of MPTP-opening and cell death in-
duction under stress conditions. We postulate that HSD10
aids in cancer cell resistance by preventing MPTP-induced
cell death via enhanced binding to CypD. Using immuno-
blot analysis, we determined that CypD protein expression
remains similar between HSD10 ov cells and EV cells
(Figure 6A). This result is consistent with other studies
of CypD in cancer [32]. Interestingly, CypD protein ex-
pression was significantly reduced in HSD10 shRNA cells
compared with control shRNA cells (Figure 6B). This indi-
cates that while CypD expression remains level during
HSD10 overexpression, it is negatively impacted by
HSD10 reduction. We suggest that, due to the reduc-
tions in both HSD10 and CypD, cancer cells become
more susceptible to cell death induction.
Additionally, we performed co-immunoprecipitation as-
says to investigate HSD10-CypD interactions in the PC-12
overexpression cell lines. As shown in Figure 6C, there is
an enhanced interaction between HSD10 and CypD in
HSD10 ov cells compared to EV cells, which was con-
firmed using both proteins as pull-down antibodies. This
indicates that increased levels of HSD10 promote the for-
mation of HSD10-CypD complexes. The co-localization
of HSD10 and CypD within mitochondria was further
confirmed via immunofluorescence (Figure 6D). The
expression pattern of CypD did not change betweenEV and HSD10 ov cells (Figure 6H), which is consist-
ent with the CypD protein expression data shown in
Figure 6A. As expected, HSD10 levels where increased
in HSD10 ov cells compared to EV cells (Figure 6G),
consistent with the results in Figure 1A-C. Co-staining
of HSD10 and CypD with the mitochondrial markers
SODII and Hsp60, respectively, confirms mitochon-
drial localization of the proteins (Figure 6E-F). Al-
though CypD expression remains constant between
EV and HSD10 ov cells, the increased expression of
HSD10 in HSD10 ov cells appears to correspond with
enhanced co-localization of HSD10 and CypD as
shown in the merged images of Figure 6D. Taken to-
gether, the results imply that an increased abundance
of HSD10 in the vicinity of CypD leads to HSD10-
CypD complex formation in PC-12 cells, conceivably
preventing cell death induction. These findings further
solidify the concept that HSD10 is important in pro-
moting cancer development and maintenance.
Discussion
We have demonstrated for the first time that PC-12
pheochromocytoma cells overexpressing HSD10 grow
significantly faster in cell culture and form larger tumors
at a faster rate in SCID mice. We theorize that HSD10
promotes enhanced cell growth through altered mito-
chondrial function, as we observed enhanced complex
IV enzyme activity and ATP production in PC-12 cells
overexpressing HSD10. Knockdown of HSD10 negatively
impacted PC-12 cell growth and mitochondrial function.
All ETC. complex activities were considerably reduced,
resulting in decreased ATP generation. This diminished
energy production is likely responsible for the reduced
growth rate observed in cell culture. We also evaluated
the possibility that HSD10 may confer protection in can-
cer cells. Upregulation of HSD10 permitted PC-12 cells
to maintain a higher functional capacity with reduced
cell death induction under chemical-induced oxidative
stress situations. Taken together, these findings provide
evidence that HSD10 mediates cancer cell growth and
resistance to death-inducing environments.
Upregulation of MPTP components correlates with in-
creased cancer cell proliferation and resistance to MPTP-
induced cell death [33,34]. Therefore, in order to uncover
the mechanism underlying HSD10-mediated cancer cell
growth and resistance, we determined whether interac-
tions existed between HSD10 and MPTP components,
such as the MPTP regulatory component, CypD. During
environmental stress, CypD translocates from the matrix
to the inner mitochondrial membrane (IMM) where it
then initiates the opening of the MPTP, consequently
leading to cell death [35]. Suppression of MPTP-induced
cell death observed in tumor cells is thought to occur due
to CypD molecular interactions which prevent IMM
Figure 6 Effect of HSD10-modification on CypD and how it may influence cancer cell growth and death. A. EV and HSD10 ov whole cell
lysates were analyzed for CypD protein expression using immunoblotting. β-actin was used as the loading control, and CypD was normalized to actin
(n = 4). B. Control shRNA and HSD10 shRNA whole cell lysates were analyzed for CypD protein expression using immunoblotting. β-actin was used as the
loading control, and CypD was normalized to actin (n = 4). C. EV and HSD10 ov whole cell lysates were analyzed for HSD10-CypD complexes using
co-immunoprecipitation. β-actin was used as the loading control for the input. The immunoblots demonstrate an increased HSD10-CypD interaction
in PC-12 cells overexpressing HSD10 compared to EV cells. D. Confocal microscopy demonstrating immunofluorescence staining of HSD10 alone (red),
CypD alone (green), and these two antigens co-localized (yellow) in EV and HSD10 ov cells. E. Immunofluorescence staining of HSD10 alone (red),
mitochondrial marker SODII alone (green), and these two antigens co-localized (yellow) in HSD10 ov cells. F. Immunofluorescence staining of CypD
alone (green), mitochondrial marker Hsp60 alone (red), and these two antigens co-localized (yellow) in HSD10 ov cells. Scale bar in F: 20 μm.
G-H. Quantification of HSD10 and CypD fluorescence densities (depicted in D) displayed as fold increase (n = 4). Data presented as mean ± SE.
*P < 0.01 versus transfected control group. I. Hypothetical mechanism of action for HSD10-mediated cancer cell growth. Top panel, cells overexpressing
HSD10 bind to CypD and sequester it in the mitochondrial matrix, thereby avoiding cell death induction; this resistance allows for continued
cancer cell proliferation. Bottom panel, cells under-expressing HSD10 cannot bind all of the available CypD; thus unbound CypD translocates to the IM
where it induces cell death via MPTP opening.
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cells from necrosis [36]. During tumorigenesis, overex-
pression of CypD inhibits cell death induction in tumor
cells due to interactions with cell death proteins, such as
anti-apoptotic Bcl-2 [37] and hexokinase II [38].
In our studies, CypD expression remained the same
in PC-12 HSD10 overexpression cell lines; however,
CypD expression was greatly reduced in HSD10 shRNA
cells. Furthermore, HSD10 and CypD exhibited en-
hanced co-localization within mitochondria and in-
creased formation of HSD10-CypD complexes in PC-12cells overexpressing HSD10. Applying this data to-
gether, Figure 6I demonstrates our model for the mech-
anism of action for HSD10-mediated cancer cell growth
and resistance to cell death. As shown on the upper half of
the figure, cancer cells overexpressing HSD10 have reduced
MPTP-mediated cell death due to enhanced interactions
between HSD10 and CypD thereby preventing CypD trans-
location to the IMM. As depicted on the lower half of
Figure 6I, cancer cells with reduced HSD10 levels are more
vulnerable to MPTP-induced cell death as fewer molecules
of HSD10 are able to bind and retain CypD in the matrix.
Carlson et al. BMC Cancer  (2015) 15:166 Page 13 of 15In addition to the HSD10-CypD interaction, this study
identified other interesting pathways. Typically, tumors ex-
hibit increased cell proliferation and resistance to cell death.
Similarly, HSD10-overexpressing PC-12 cells demonstrated
an enhanced cell growth rate and resistance to cell death
induced by oxidative stressors. This phenomenon is
likely due to altered processes within mitochondria, as
large amounts of HSD10 localized with mitochondria
in HSD10-overexpressing cells. Although the Warburg
effect of elevated glycolytic ATP production in cancer cells
is widely recognized [39], many groups have revealed that
mitochondria in tumor cells are able to operate both re-
spiratory pathways [40]. As we observed elevated complex
IV activity in HSD10-overexpressing cells, we postulate that
HSD10 provides additional energy metabolites for the cells.
Among its many functions, HSD10 metabolizes
β-hydroxybutyrate (BHB), which can be used as an en-
ergy source when blood glucose levels are low [41].
Studies have shown that tumor animal models utilize
BHB as an energy source. For instance, it has been ob-
served that BHB concentrations increased in the tumors
of nude rats as tumor blood flow decreased [42]. Add-
itionally, it was recently discovered that BHB is upregu-
lated in caveolin-1 null mice and proposed that epithelial
cancer cells directly take in stromal-derived BHB to drive
tumor progression and eventual metastasis [43]. With
cancer cells already displaying heightened ATP production
due to the two principal energy metabolism pathways, the
addition of another source of energy via the enzymatic
capability of HSD10 would increase ATP generation even
further. This could lead not only to alterations in mito-
chondrial bioenergetics, but also to changes in mitochon-
drial signal transduction pathways, particularly resistance
to cell death.
Most often, cancer cells have disrupted cell death path-
ways due to mutations that either inhibit pro-apoptotic
proteins [44] or elevate anti-apoptotic proteins [45]. As
depicted by the model in Figure 6I, the suppression of
MPTP-mediated apoptosis is due to the sequestration of
CypD by HSD10; our future efforts will focus on this path-
way. Additionally, CypD has been shown to interact with
anti-apoptotic proteins, including Bcl-2. It is possible
HSD10 may bind to CypD and displace Bcl-2, allowing
Bcl-2 to prevent apoptosis. Validation of the role of Bcl-2
in this mechanism will require additional studies. Also, as
HSD10 is a versatile enzyme within cells, further inquiry
into its potential role in the repression of oxidative stress-
induced cell death would be an interesting undertaking.
Lastly, using an in vivo xenograft mouse model, we
showed that HSD10-overexpressing cells grew faster and
larger over 32 days as opposed to vector control tumors.
While there are limited in vivo xenograft studies involving
PC-12 cells, one group revealed that following implant-
ation of PC-12 cells into the striatum of Sprague–Dawleyrats, the number of cells remained unchanged without
continued tumor growth [46]. This study supports the
minimal growth observed in our EV tumors and provides
further support for the tumorigenic ability of HSD10
(Figure 4C-D).
The data presented here provides a promising platform
for further research to elucidate the mechanism under-
lying HSD10-mediated cancer cell growth and cell death
resistance. Our laboratory recently created small molecule
inhibitors of HSD10 [47]. As HSD10 overexpression
grants pheochromocytoma cells enhanced cellular prolif-
erative and cell death resistant capabilities, targeted in-
hibition of HSD10 in cancer cells may provide a novel
treatment method. Furthermore, now that we have veri-
fied that HSD10 is important in adrenal gland tumor cell
development, we intend to investigate its role in other hu-
man cancers. The effect of HSD10 in breast cancer devel-
opment will be especially compelling as HSD10 is able to
regulate estrogen steroidogenesis [10]. Furthermore, fel-
low HSD10 family member HSD17B type 1 was discov-
ered as a novel target for endocrine therapy in certain
breast cancer patients [48]. Evaluating the effect of HSD10
on human cancers would then provide more information
as to its translational implications as a biomarker or treat-
ment target.
Conclusions
In summary, we have provided substantial evidence dem-
onstrating that HSD10 overexpression significantly in-
creased pheochromocytoma cell growth in cell culture
and in vivo. The increases in respiratory enzymes and en-
ergy generation observed in HSD10-overexpressing cells
likely supported the accelerated growth rate. Furthermore,
HSD10 upregulation provided added protection against
oxidative stress stimuli. These findings indicate that
HSD10 is involved in cancer cell growth and develop-
ment. This study shows that HSD10 provides a promis-
ing novel target for cancer therapy.
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